KBC Group NV Grows Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

KBC Group NV raised its position in ADMA Biologics Inc (NASDAQ:ADMA) by 11.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,217 shares of the biotechnology company’s stock after purchasing an additional 1,154 shares during the period. KBC Group NV’s holdings in ADMA Biologics were worth $223,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Bank of New York Mellon Corp lifted its holdings in ADMA Biologics by 10.8% in the 4th quarter. Bank of New York Mellon Corp now owns 1,521,166 shares of the biotechnology company’s stock valued at $26,088,000 after purchasing an additional 147,748 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of ADMA Biologics by 2.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after acquiring an additional 751 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of ADMA Biologics by 303.4% during the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 4,312 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of ADMA Biologics by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,440,294 shares of the biotechnology company’s stock worth $41,851,000 after acquiring an additional 38,761 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of ADMA Biologics by 52.8% during the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company’s stock worth $1,886,000 after acquiring an additional 38,002 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 0.9%

ADMA opened at $18.30 on Monday. The firm has a 50 day moving average price of $20.24 and a 200 day moving average price of $18.73. The company has a market cap of $4.37 billion, a PE ratio of 21.52 and a beta of 0.43. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm’s revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period last year, the company posted $0.08 EPS. Sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company’s stock, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company’s stock, valued at $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 464,621 shares of company stock valued at $9,644,269. 3.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Raymond James Financial increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.